XXXX as rescue medication in anthracycline- and @entity1260 -resistant locally advanced or metastatic soft tissue @entity242 : results of a phase II trial.

@entity1 @entity137 @entity242 @entity8253 @entity1260 @entity1205
BACKGROUND: Metastatic soft tissue @entity242 not amenable to curative surgery has a dismal prognosis. Aggressive treatment with @entity8253 and @entity1260 represents the current therapeutic mainstay in these @entity1 , most of whom succumb to relapses. Thus, the efficacy of subsequent therapeutic approaches has to be weighed against @entity137 caused by palliative treatment. @entity1 AND METHODS: @entity1 with locally advanced or metastatic soft tissue @entity242 refractory to treatment with @entity8253 and @entity1260 were enrolled into the present phase II study. @entity1 were assigned to receive @entity1205 at 100 mg/m2 every three weeks. In case of severe @entity137 , @entity1 were switched to a weekly schedule of @entity1205 (40 mg/m2). RESULTS: A total of 106 cycles (80% at the scheduled 100 mg/m2 dose level) were administered in 27 @entity1 . Partial response was observed in 4 (15%) @entity1 and 4 (15%) @entity1 experienced disease stabilization. Median progression free survival and overall survival were 2.4 (range: 0.9-23.9) and 7.7 (range: 1.0-44.3) months, respectively. Upon renewed progression, three @entity1 initially responsive to treatment with @entity1205 were successfully reinduced by treatment with @entity1205 . The safety profile of @entity1205 was tolerable and the administration mostly manageable on an outpatient basis. CONCLUSIONS: Our results suggest that @entity1205 represents an efficacious and tolerable treatment in a minority of @entity1 refractory to standard treatment. There is a need for better identification of @entity1 most likely to benefit from salvage treatment with @entity1205 .
